Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioXcel Therapeutics (BTAI) Other Accumulated Expenses (2022 - 2025)

BioXcel Therapeutics (BTAI) has 4 years of Other Accumulated Expenses data on record, last reported at $450000.0 in Q3 2025.

  • For Q3 2025, Other Accumulated Expenses rose 82.19% year-over-year to $450000.0; the TTM value through Sep 2025 reached $450000.0, up 82.19%, while the annual FY2024 figure was $322000.0, 81.92% up from the prior year.
  • Other Accumulated Expenses reached $450000.0 in Q3 2025 per BTAI's latest filing, up from $366000.0 in the prior quarter.
  • Across five years, Other Accumulated Expenses topped out at $820000.0 in Q4 2022 and bottomed at $152000.0 in Q1 2022.
  • Average Other Accumulated Expenses over 4 years is $410000.0, with a median of $366000.0 recorded in 2025.
  • The widest YoY moves for Other Accumulated Expenses: up 218.42% in 2023, down 78.41% in 2023.
  • A 4-year view of Other Accumulated Expenses shows it stood at $820000.0 in 2022, then tumbled by 78.41% to $177000.0 in 2023, then skyrocketed by 81.92% to $322000.0 in 2024, then skyrocketed by 39.75% to $450000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Other Accumulated Expenses were $450000.0 in Q3 2025, $366000.0 in Q2 2025, and $423000.0 in Q1 2025.